Jubilant Ingrevia Ltd. · NSE:JUBLINGREA
Jubilant Ingrevia — Q3 FY2025 Earnings Presentation
38 slides from Jubilant Ingrevia's earnings presentation, Jan 29, 2025
Slide 1: Exchange filing cover letter: Investors Presentation
January 28, 2025 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E) Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Sub: Investors Presentation Dear Sirs, In terms of Regulation
Slide 2: Jubilant Ingrevia Limited Investor Presentation January 2025
Jubilant Ingrevia Limited Investor Presentation January 2025 1
Slide 3: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 4: Chairmen's Message on Q3'FY25 Financial Results | 1/2
Chairmen’s Message on Q3’FY25 Financial Results | 1/2 “We are pleased to announce significant year-on-year growth for this quarter, attributed to the enhanced performance of our Specialty Chemicals and Nutrition businesses, as well as to the benefits derived from cost-saving initiatives implemented
Slide 5: Chairmen's Message on Q3'FY25 Financial Results | 2/2
Chairmen’s Message on Q3’FY25 Financial Results | 2/2 The Nutrition and Health Solutions Business segment experienced continued Y.o.Y and Q.o.Q volume growth, primarily driven by significant volume increases in choline products, while Niacinamide volumes remained stable. We also saw uptick in Niacin
Slide 6: Table of Contents
Table of Contents 0 6 Company Overview 1 1 Growth Roadmap 1 5 Q3’FY25 Highlights 2 1 Business Segments Update 5
Slide 7: Company Overview
Company Overview Visuals of our New Plant for Cosmetic & Food Grade Vitamin B3 in Bharuch 6 6
Slide 8: Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group
Jubilant Ingrevia is the oldest and third largest company in Jubilant Bhartia Group 45+ years 2300+ people 3rd largest of legacy in Chemicals space, started with strong leadership team with Company in the Jubilant Group average 25+ years of experience in in 1978 as VAM Organic Chemicals Chemicals sp
Slide 9: Our business is split across 3 business verticals
Our business is split across 3 business verticals, with global leadership across our key product lines 44% Revenue Mix 18% Revenue Mix 38% Revenue Mix 72% EBITDA Mix # 15% EBITDA Mix # 13% EBITDA Mix # Specialty Chemicals Nutrition & Health Solutions Chemical Intermediates CDMO (Pharma, Agro, Semi
Slide 10: We serve customers across geographies and sectors
We serve customers across geographies and sectors; increased growth from exports and pharma/cosmetic/nutrition sectors in recent years Our Product Platforms Enable us to serve diverse customer segments and market needs 1• Pyridine Geographical Revenue Split End-use Industry Revenue Split 2• Diketene
Slide 11: Executive Leadership Team
Executive Leadership Team Deepak Jain Chandan Singh CEO & MD Advisor Energized & experienced leadership team 20 years of industry & 37 years of industry Consulting experience experience Business Leaders Function Leaders Specialty Chemicals Nutrition & Health Chemical Intermediates Ambrish Dixit Ashi
Slide 12: Growth Roadmap (Recap)
Growth Roadmap (Recap)
Slide 13: Our new 'Compass' forms the bedrock of our future growth roadmap
Our new ‘Compass’ forms the bedrock of our future growth roadmap PURPOSE VISION Enable a Sustainable World through Leading provider of innovative solutions Chemistry in our core chemistries globally Customer Centricity World-class, Safe Innovation & ESG Leader People Focused Operations Technology Cu
Slide 14: Recap: Future Growth Aspiration to grow 3x - PINNACLE 3.4.5
Recap: Future Growth Aspiration to grow 3x in next 5 years PINNACLE 3.4.5 13
Slide 15: Last one year: progress in our Pinnacle 345 journey
Last one year: We have already started to make good progress in our Pinnacle 345 journey Major events / milestones Creation of a tight budget with 120 Turnaround in Received WEF Cr+ of Lean/Surge/BE initiatives Specialty and Lighthouse Nutrition with award at Davos Commissioning of DIKETENE increase
Slide 16: Q3 & 9M'FY25 Highlights
Q3 & 9M’FY25 Highlights 15 15
Slide 17: Market Overview: Volumes recovering across segments, but prices remain muted
Market Overview: Q3 & 9M’FY25 | Volumes recovering across segments, but prices remain muted PHARMA • Experiencing steady demand with volume visibility across segments, and notable volume growth in pyridine derivatives. • Prices being stable across segments, with some areas experiencing an uptick. •
Slide 18: Key business highlights Q3FY25
Key business highlights Q3FY25: Continued growth momentum in our core categories, higher margins on account of product mix & cost initiatives • Pyridine & Picoline: Significant volume growth on YoY basis; Prices moved up in some segments Core product platforms continue to • Niacinamide: Maintained l
Slide 19: Financial Results Overview | Q3 & 9M'FY25 Consolidated
Financial Results Overview | Q3 & 9M’FY25 Consolidated 1 Particulars Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y Total Revenue 966 1,045 1,057 1.1% 9.4% 3,061 3,126 2.1% Total EBITDA 104 135 148 9.4% 41.5% 356 402 12.9% EBITDA Margin (%) 11% 13% 14% 12% 13% Profit After Tax 39 59 69 17
Slide 20: Our recovery in EBITDA and growth momentum continues
Our recovery in EBITDA and growth momentum continues from the lows of H2FY24 Despite the pressure on acetyl volumes, we have achieved significant overall volume growth. 20.0% 160 148 EBITDA (INR Crs.) EBITDA Margins 18.0% 135 140 125 126 Highest EBITDA 119 Margin in last 11 16.0% 120 quarters 104 10
Slide 21: EBITDA growth in Specialty Chemicals and Nutrition
EBITDA growth| We continue to see secular YoY EBITDA growth across Specialty Chemicals and Nutrition along with margin expansion in Specialty Specialty Chemicals Nutrition & Health Solutions EBITDA (Rs Cr.) EBITDA (Rs Cr.) Y.o.Y Growth 120% Y.o.Y Growth 44% Q.o.Q Growth 39% Q.o.Q Growth 4% 24 25 121
Slide 22: Business Segments Overview
Business Segments Overview 21
Slide 23: Specialty Chemicals | Market, Business & Financial Highlights
1 Specialty Chemicals | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Consistent demand improvement from the end-use segment kept volumes strong, while 1 pricing remained stable with increases in Particulars Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y s
Slide 24: Nutrition & Health Solutions | Market, Business & Financial Highlights
2 Nutrition & Health Solutions | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Increased sales volume on YoY basis. 1 Particulars Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y Witnessed improved Niacinamide pricing on Segment Revenue 151 182 190 4% 25% 51
Slide 25: Chemical Intermediates | Market, Business & Financial Highlights
3 Chemical Intermediates | Market, Business & Financial Highlights MARKET HIGHLIGHTS FINANCIAL HIGHLIGHTS Headwinds continues from the primary end-use markets for Paracetamol Particulars 1 Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y Higher YoY and QoQ volumes of Ethyl Acetate Segment R
Slide 26: Annexures
Annexures 25 25
Slide 27: Annexure I - Income Statement | Consolidated
Annexure I - Income Statement | Consolidated – Q3 & 9M‘FY25 Particulars1 Q3'FY24 Q2'FY25 Q3'FY25 QoQ YoY 9M'FY24 9M'FY25 YoY Revenue from operations a) Sales/Income from operations 960 1029 1046 2% 9% 3040 3086 1% b) Other operating income 6 16 11 -34% 80% 21 41 93% Total revenue from operations 966
Slide 28: Annexure II: Income Statement Segmental
Annexure II: Income Statement Segmental – Q3 & 9M’FY25 Particulars1 Q3'FY24 Q2'FY25 Q3'FY25 QoQ (%) YoY (%) 9M'FY24 9M'FY25 YoY (%) Total Revenue from Operations 966 1,045 1,057 1% 9% 3,061 3,126 2% Speciality Chemicals 365 433 468 8% 28% 1,110 1,331 20% Nutrition & Health Solutions 151 182 190 4% 2
Slide 29: Annexure III: Debt Position as on 31st December 2024
Annexure III: Debt Position| As on 31st December 2024 1 Particulars 31-Dec-23 30-Sep-24 31-Dec-24 Long Term Borrowings 300 450 457 Short Term Borrowings 395 263 291 Total Gross Debt 695 713 748 Cash & Equivalent 58 63 67 Total Net Debt 636 650 681 YoY change 7% • The capex for the quarter was Rs 92
Slide 30: Annexure III - Conference Call Details
Annexure III - Conference Call Details Diamond Pass Log-In Date : January 28th, 2025 Time : 05:00 pm IST To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, p
Slide 31: Thank you for your time
For More Information Jubilant Ingrevia Limited is a globally integrated Life Sciences & For Investors: Specialty Chemicals company, serving Pharmaceutical, Nutrition, Agrochemical, Consumer and Industrial customers. It has a broad Pavleen Taneja portfolio of over 130+ products and customized solutio
Slide 32: Jubilant Ingrevia Limited – Q3 & 9M FY25 Results Press Release
Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 PRESS RELEASE www.jubilantingrevia.com Noida, Tuesday, January 28th, 2025 JUBILANT INGREVIA LIMITED – Q3 & 9M FY25 RESULTS 1 Particulars Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y Total Revenue 966 1
Slide 33: Q3'FY25 Highlights | Segment Wise Analysis A. Speciality Chemicals
The Nutrition and Health Solutions Business Segment experienced continued Y.o.Y and Q.o.Q volume growth, primarily driven by significant volume increases in choline products, while Niacinamide volumes remained stable. We also saw uptick in Niacinamide prices last quarter. In the Chemical Intermediat
Slide 34: B. Nutrition & Health Solutions
CDMO - Experienced QoQ increase in volumes, driven by a growing number of inbound inquiries from the Agro, Pharma, and Semiconductor sectors Business Highlights - The CDMO business continued to get good traction; capital expenditure initiated for two agrochem orders announced in last quarter - The h
Slide 35: C. Chemical Intermediates Segment
C. .Chemical Intermediates Segment 1 Particulars Q3'FY24 Q2'FY25 Q3'FY25 Q-o-Q Y-o-Y 9M'FY24 9M'FY25 Y-o-Y Segment Revenue 450 430 400 -7% -11% 1,436 1,237 -14% % Share of Overall Revenue 47% 41% 38% 47% 40% EBITDA 48 40 22 -46% -55% 159 97 -39% % EBITDA Margin 11% 9% 5% 11% 8% % Contribution to EBI
Slide 36: Income Statement and Segment P&L – Q3'FY25
3. Income Statement – Q3’FY25 Particulars1 Q3'FY24 Q2'FY25 Q3'FY25 QoQ YoY 9M'FY24 9M'FY25 YoY Revenue from operations a) Sales/Income from operations 960 1029 1046 2% 9% 3040 3086 1% b) Other operating income 6 16 11 -34% 80% 21 41 93% Total revenue from operations 966 1045 1057 1% 9% 3061 3126 2%
Slide 37: Debt Position as on 31st December, 2024
5. Debt Position as on 31st December, 2024 1 Particulars 31-Dec-23 30-Sep-24 31-Dec-24 Long Term Borrowings 300 450 457 Short Term Borrowings 395 263 291 Total Gross Debt 695 713 748 Cash & Equivalent 58 63 67 Total Net Debt 636 650 681 YoY change 7% All figures are in Rs Crore unless otherwise stat
Slide 38: For more information, please contact
For more information, please contact: For Investors Pavleen Taneja Siddharth Rangnekar Jubilant Ingrevia Limited CDR India Ph: +91-120 436 1000 Ph: +91 22 6645 1209 E-mail: [email protected] E-mail: [email protected] For Media Sandipan Ghatak Ryan Marshall Ph: +91-120 436 1062 M: +91 981